Skip to Main Content

Paper Details

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
48
2019
Down syndrome, HER2, Lapatinib, Trastuzumab, anti-, breast cancer, early breast cancer, human, human epidermal growth factor receptor 2, human epidermal growth factor receptor 2-positive early breast cancer, lapatinib, patients, trastuzumab, trisomy 21
Author NameAffiliation
Florentine S Hilbers
Larissa A KordeNational Cancer Institute
José BaselgaMemorial Sloan Kettering Cancer Center
  • 1 - 3

Datasets

Release 1.2